Lisata Therapeutics Reports Positive Results for Certepetide in Treating Pancreatic Cancer

Summary

Lisata Therapeutics Inc. reported positive preliminary results from the ‘ASCEND’ Phase 2b trial Group B for certepetide in the treatment of metastatic pancreatic cancer. Conducted in collaboration with the NHMRC Clinical Trials Centre, the trial showed good signals in progression-free survival and objective response rate compared to a placebo. These findings support early results from Group A, indicating effective and safe treatment. Full research data is expected later this year, with a presentation scheduled at the European Society for Medical Oncology Gastrointestinal Cancer Conference on July 2, 2025.Reuters

Impact Analysis

The positive results from the ASCEND Phase 2b trial represent a significant product milestone for Lisata Therapeutics, enhancing prospects for certepetide as a treatment for metastatic pancreatic cancer. First-order effects include improved growth prospects and potential market advantages due to the promising efficacy and safety profile demonstrated, which might attract more investors and increase the company’s valuation. However, risks involve regulatory scrutiny, typical in drug development, and potential competitive pressures from other treatments in the market. Second-order effects may be seen in the pharmaceutical industry, as peer companies might respond with competitive strategies or collaborations. Investment opportunities could arise in the form of strategic partnerships or acquisition interests in Lisata Therapeutics due to the promising clinical results.Reuters